

CHRONIC HEPATITIS C

Information brochure for patients under new direct acting antivirals

D. DOMNGANG¹, S. LORENT², C. MORENO³

²Medico Pharmaceutical Products and ³Gastroenterology departments, Erasme Hospital, Brussels, Belgium

BACKGROUND

Viral Hepatitis C is a disease transmitted by hepatitis C virus (HCV) after direct contact with infected blood. Arrival on the Belgian pharmaceutical market of new oral direct acting antiviral (DAA) agents in 2015, has changed the landscape of therapeutic care of patients. Virologic response with these new DAA is excellent and varies between 90% and 95%. These new DAA drugs however present a risk of development of resistance in the event of no respect of posology, side effects although reduced and multiple potential drug-drug interactions. Standard and appropriate information to the patient is important, in order to achieve the goal of VHC eradication.

PURPOSE

- Develop and implement a therapeutic educational tool for patients with chronic hepatitis C.
- Inform and communicate effectively with patients under new oral DAA agents available in Belgium.

METHODS

- Review of scientific literature and recommendations on hepatitis C and new direct acting antivirals in 2015 : PubMed*, EASL*, AFEF*, AASLD*, AFMPS-RCP*, hep-drug interactions.org*, CBIP*, various pharmaceutical guide books.
- Analysis of scientific information and drafting of drug leaflets for HCV drugs already on the Belgian market in 2015.
- Writing of the information brochure (A6 format).
- Validation of the content in multidisciplinary collaboration between pharmacists and hepatologists.

RESULTS

INFORMATION BROCHURE ON HEPATITIS C WRITTEN IN FRENCH



Information brochure with several sections

General information

Chronic hepatitis C

Introduction







Viral hepatitis C & Virus

Viral hepatitis C & Treatment

Viral hepatitis C & Drug information



6 DRUG LEAFLETS



CONCLUSION

- Implementation of information brochure allows to the pharmacist, to provide a well summarized information during VHC treatment's initiation.
- The possibilities of pharmacist's involvement in the follow-up of VHC patients are wide.
- Hospital pharmacist is a key point in the management of chronic hepatitis C in Belgium.

REFERENCES

- PubMed : Data base containing scientific literature from various sources.
- EASL : European Association for the Study of the Liver.
- AFEF : French Association for the Study of the Liver.
- AASLD : American Association for the Study of the Liver.
- Belgian Health Drugs and Products Agency – Summary of Product Characteristics.
- CBIP : Belgian Center of Pharmaco-therapeutic Information.
- Hep-druginteractions.org : Data base for drug-drug interactions in chronic hepatitis C treatment.